세계의 좌골신경통 치료 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 투여 경로별, 유통 채널별, 지역별 부문 예측(2025-2033년)

Sciatica Treatment Market Summary

The global sciatica treatment market size was estimated at USD 5.15 billion in 2024 and is projected to reach USD 10.71 billion by 2033, growing at a CAGR of 8.40% from 2025 to 2033. This growth is attributed to several key factors, including the rising global prevalence of sciatica, aging populations, and advancements in treatment modalities.

The sciatica treatment market is experiencing significant growth, driven by several key factors that reflect broader trends in healthcare, patient care, and technological advancements. One of the primary drivers is the aging global population. As people live longer, the incidence of musculoskeletal conditions like sciatica increases. According to the World Health Organization, October 2024, By 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million, with a significant rise in chronic conditions such as sciatica. This demographic is particularly vulnerable to chronic conditions like sciatica.

As the number of older adults rises, so does the demand for effective treatment options to address the chronic pain and mobility issues associated with sciatica. This trend is especially noticeable in regions like North America and Europe, where a significant proportion of the population is aging. The Centers for Disease Control and Prevention (CDC) has identified musculoskeletal disorders (MSDs) as a leading cause of disability among U.S. adults. These disorders encompass conditions such as back pain, joint injuries, tendinitis, and repetitive strain. They can cause temporary or even permanent disability, leaving some individuals unable to move around easily. Work-related MSDs are particularly prevalent among people during their working years, contributing to a rise in demand for sciatica treatments. Consequently, healthcare systems in these regions are focusing on developing and providing specialized treatment options for older patients, thus contributing to market expansion.

Furthermore, the development of biologic treatments, such as stem cell therapy and platelet-rich plasma (PRP) injections, offers potential for more targeted and effective management of sciatica, especially in cases involving disc degeneration or nerve damage. Given the rise in research on PRP's potential benefits for conditions like chronic lower back pain, it is plausible that treatments like these could be explored for sciatica in the future. In the same period, Mayo Clinic continued to offer more conventional treatments for sciatica, such as physical therapy, medications, and injections (like epidural steroids), which have been well-established as effective for managing sciatica-related pain. As new technologies continue to emerge, treatment options will diversify, creating opportunities for market growth and innovation.

Another important driver is the increasing awareness of sciatica and its available treatment options. As public awareness around chronic pain conditions and musculoskeletal disorders rises, more patients are seeking diagnosis and management for sciatica symptoms. According to the Centers for Disease Control and Prevention (CDC), data from the National Health Interview Survey in 2023 revealed that 24.3% of U.S. adults had chronic pain, and 8.5% had high-impact chronic pain that frequently limited life or work activities. Chronic pain and high-impact chronic pain are among the most common reasons adults seek medical care. Healthcare providers are also increasingly emphasizing early intervention, which helps reduce long-term disability and improves overall patient outcomes.

In addition to growing awareness, there is a greater focus on improving access to treatment, especially in developing regions. The expansion of healthcare infrastructure in regions like Asia Pacific and Latin America is facilitating greater access to both traditional and modern treatment options. For example, in March 2023, the World Bank approved funding to improve healthcare infrastructure in India, including the expansion of spine care services. This is expected to support a greater demand for sciatica treatments in the region.

Furthermore, the increasing availability of telemedicine services and home care options is also allowing for broader access to treatment, particularly for patients in remote or underserved areas. This growing accessibility, combined with higher awareness and advancements in treatment methods, positions the sciatica treatment market for continued expansion in the coming years.

Global Sciatica Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global sciatica treatment market report based on product, route of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Analgesics & NSAIDs
• Neuropathic Pain Agents
• Corticosteroids
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Topical
• Parenteral / Injectable
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacy
• Hospital Pharmacy
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Sciatica Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Sciatica Treatment Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Analgesics & NSAIDs
  • 4.4.1. Analgesics & NSAIDs Market, 2021 - 2033 (USD Million)
• 4.5. Neuropathic Pain Agents
  • 4.5.1. Neuropathic Pain Agents Market, 2021 - 2033 (USD Million)
• 4.6. Corticosteroids
  • 4.6.1. Corticosteroids Market, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Sciatica Treatment Market: Route of Administration Business Analysis

• 5.1. Route of Administration Market Share, 2024 & 2033
• 5.2. Route of Administration Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 5.4. Oral
  • 5.4.1. Oral Market, 2021 - 2033 (USD Million)
• 5.5. Topical
  • 5.5.1. Topical Market, 2021 - 2033 (USD Million)
• 5.6. Parenteral / Injectable
  • 5.6.1. Parenteral / Injectable Market, 2021 - 2033 (USD Million)

Chapter 6. Sciatica Treatment Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Sciatica Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Uk Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Sciatica Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. AbbVie Inc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Disease Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Teva Pharmaceutical Industries Ltd.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Disease Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Sun Pharmaceutical Industries Ltd.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Disease Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Glenmark Pharmaceuticals Ltd.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Sorrento Therapeutics Inc.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Medtronic plc
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Boston Scientific Corporation
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Pfizer Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Johnson & Johnson
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Abbott Laboratories
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives